Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Date:3/20/2009

bination with a standard dosage of docetaxel. Eligible patients included those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The poster presentation will be available on the Oncolytics website today at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the REOLYSIN(R)/docetaxel trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize RE
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
2. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
3. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
4. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
8. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
9. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
10. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
11. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittcon is pleased to announce that the 2015 ... Scientific, have organized a session on nanotechnology for presentation ... Asia’s largest analytical and scientific instruments show, will be ... , The four speakers in this U.S. symposium, “Thinking ... Single Cells” will present their use of nanotechnology to ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3, Shire ... biopharmaceutical company, notes that Renovo Group plc, (LSE:,RNVO) ... latest Phase 2,studies of JUVISTA(R) (human recombinant TGFbeta3) ... (RN1001-319-1010)., Renovo’s press release can be found ...
... and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... company,focused on endocrine therapy and oncology, and Paladin ... company, announced today,that they have entered into a ... rights related to the manufacture, production, distribution,marketing, sale ...
... Feb. 29 Wyeth Pharmaceuticals,a division of Wyeth ... U.S. Food and,Drug Administration (FDA) has approved PRISTIQ(TM) ... treat adult patients with major depressive disorder (MDD). ... in the second,quarter of 2008., "We are ...
Cached Biology Technology:Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
(Date:8/28/2014)... mobile app called TX Invasives is now available from ... of Texas at Austin for identifying harmful non-native plant, ... species in the United States cause about $137 billion ... agricultural crops, clog waterways, kill native plants and more. ... app for reporting where invasive species occur, we,re more ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... Experimental Biology and Medicine has established the Distinguished Scientist ... have established them as leaders in biomedicine, and who ... of the Society have been named as the 2012 ... an awards ceremony on April 22nd in San Diego. ...
... (AZM) has been the most used insecticide in apple production ... a control for the codling moth, but a decision by ... end of this product,s use by tree fruit growers. ... to replace AZM. These new insecticides have unique modes of ...
... lizard moms tend to give their developing embryos short ... thing for the babies once they,re born, according to ... Biochemical Zoology. Stress changes the way animals ... are released that help the body to access stored ...
Cached Biology News:Lizard moms may prepare their babies for a stressful world 2
Pim-1 (12H8)...
Ets-1...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: